$4.88
Insights on Affimed Nv
Revenue is down for the last 2 quarters, 1.96M → 413.0K (in $), with an average decrease of 79.0% per quarter
Netprofit is up for the last 4 quarters, -31.98M → -20.20M (in $), with an average increase of 16.7% per quarter
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 93.1%
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 336.3%
0.31%
Downside
Day's Volatility :10.49%
Upside
10.21%
54.1%
Downside
52 Weeks Volatility :79.82%
Upside
56.04%
Period | Affimed Nv | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -15.35% | 1.7% | 0.0% |
6 Months | 46.77% | 11.3% | 0.0% |
1 Year | -43.39% | 5.4% | 1.3% |
3 Years | -95.71% | 13.9% | -22.1% |
Market Capitalization | 76.1M |
Book Value | $3.85 |
Earnings Per Share (EPS) | -7.56 |
PEG Ratio | 0.0 |
Wall Street Target Price | 22.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -382.46% |
Return On Assets TTM | -43.5% |
Return On Equity TTM | -100.55% |
Revenue TTM | 13.9M |
Revenue Per Share TTM | 0.93 |
Quarterly Revenue Growth YOY | -58.3% |
Gross Profit TTM | 42.9M |
EBITDA | -102.6M |
Diluted Eps TTM | -7.56 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.22 |
EPS Estimate Next Year | -3.77 |
EPS Estimate Current Quarter | -1.67 |
EPS Estimate Next Quarter | -1.44 |
What analysts predicted
Upside of 361.07%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 27.2M | ↑ 1080.85% |
Net Income | -22.3M | ↓ 35.56% |
Net Profit Margin | -82.06% | ↑ 1421.57% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 24.0M | ↓ 9.88% |
Net Income | -36.3M | ↑ 66.17% |
Net Profit Margin | -151.3% | ↓ 69.24% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 34.9M | ↑ 32.58% |
Net Income | -50.9M | ↑ 27.81% |
Net Profit Margin | -145.86% | ↑ 5.44% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 45.7M | ↑ 42.33% |
Net Income | -65.1M | ↑ 39.06% |
Net Profit Margin | -142.5% | ↑ 3.36% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 44.3M | ↑ 2.45% |
Net Income | -92.1M | ↑ 49.51% |
Net Profit Margin | -207.98% | ↓ 65.48% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 8.3M | ↓ 79.99% |
Net Income | -105.9M | ↑ 23.18% |
Net Profit Margin | -1.3K% | ↓ 1072.24% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 14.6M | ↑ 103.92% |
Net Income | -13.5M | ↓ 19.73% |
Net Profit Margin | -92.5% | ↑ 142.48% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 4.8M | ↓ 69.71% |
Net Income | -34.3M | ↑ 132.25% |
Net Profit Margin | -709.16% | ↓ 616.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.9M | ↑ 0.0% |
Net Income | -34.9M | ↑ 0.0% |
Net Profit Margin | -709.16% | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.5M | ↓ 69.18% |
Net Income | -32.1M | ↓ 8.09% |
Net Profit Margin | -2.1K% | ↓ 1405.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.0M | ↑ 41.15% |
Net Income | -24.4M | ↓ 17.15% |
Net Profit Margin | -1.2K% | ↑ 873.41% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 413.0K | ↓ 78.95% |
Net Income | -20.2M | ↓ 17.04% |
Net Profit Margin | -4.9K% | ↓ 3650.91% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 132.9M | ↑ 169.18% |
Total Liabilities | 87.0M | ↑ 556.75% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 125.9M | ↓ 3.28% |
Total Liabilities | 82.5M | ↓ 3.09% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 216.1M | ↑ 56.4% |
Total Liabilities | 127.6M | ↑ 40.76% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 255.0M | ↑ 28.12% |
Total Liabilities | 101.0M | ↓ 14.02% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 214.8M | ↓ 10.94% |
Total Liabilities | 51.0M | ↓ 46.63% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 97.2M | ↓ 51.55% |
Total Liabilities | 39.4M | ↓ 17.33% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 232.4M | ↓ 9.39% |
Total Liabilities | 54.4M | ↓ 18.78% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 179.9M | ↓ 28.95% |
Total Liabilities | 45.9M | ↓ 22.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 183.2M | ↑ 0.0% |
Total Liabilities | 46.7M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 147.0M | ↓ 19.79% |
Total Liabilities | 39.0M | ↓ 16.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 120.5M | ↓ 10.58% |
Total Liabilities | 44.0M | ↑ 23.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 97.2M | ↓ 19.35% |
Total Liabilities | 39.4M | ↓ 10.66% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 56.6M | ↓ 293.5% |
Investing Cash Flow | -17.9M | ↓ 293.91% |
Financing Cash Flow | 23.4M | ↓ 13.88% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.5M | ↓ 158.77% |
Investing Cash Flow | 4.9M | ↓ 127.8% |
Financing Cash Flow | 29.2M | ↑ 27.05% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.9M | ↓ 33.23% |
Investing Cash Flow | 9.8M | ↑ 84.47% |
Financing Cash Flow | 85.2M | ↑ 165.97% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -98.1M | ↑ 346.35% |
Investing Cash Flow | -4.4M | ↓ 148.09% |
Financing Cash Flow | 151.3M | ↑ 92.89% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.7M | ↓ 28.15% |
Investing Cash Flow | 2.1M | ↑ 50.7% |
Financing Cash Flow | -465.9K | ↓ 100.53% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -35.6M | ↑ 74.71% |
Investing Cash Flow | -3.2K | ↓ 100.14% |
Financing Cash Flow | -679.2K | ↑ 33.76% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -36.3M | ↑ 0.0% |
Investing Cash Flow | -3.3K | ↑ 0.0% |
Financing Cash Flow | -691.4K | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -36.4M | ↑ 0.26% |
Investing Cash Flow | -3.3K | ↑ 0.0% |
Financing Cash Flow | -2.8M | ↑ 306.94% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.3M | ↓ 45.24% |
Investing Cash Flow | -37.5M | ↑ 1248400.0% |
Financing Cash Flow | -1.6M | ↓ 37.6% |
Sell
Neutral
Buy
Affimed Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Affimed Nv | -5.97% | 46.77% | -43.39% | -95.71% | -85.3% |
Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Affimed Nv | NA | NA | 0.0 | -5.22 | -1.01 | -0.43 | NA | 3.85 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Affimed Nv | Buy | $76.1M | -85.3% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
683 Capital Management LLC
NEA Management Company, LLC
Point72 Asset Management, L.P.
Millennium Management LLC
Eversept Partners, LLC
Morgan Stanley - Brokerage Accounts
Affimed Nv’s price-to-earnings ratio stands at None
Read Moreaffimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Organization | Affimed Nv |
Employees | 76 |
CEO | Dr. Andreas Harstrick M.D. |
Industry | Health Technology |